Skip to content
paiva

decision intelligence software for early neuropsychiatric drug development

a better way to make drug development decisions

paiva helps early-stage biotech teams define what their next milestone must establish, interactively evaluate development paths against evidence and resource constraints, and build a strategy they can defend as the evidence changes

01 / the challenge

the value of your next milestone is shaped by the decisions that lead to it

a choice about dose, study design or development sequence changes more than the next readout — it affects what the program can prove, what other functions must deliver and which options remain open

start

milestone ambition

  • therapeutic differentiation
  • clinical evidence strategy
  • regulatory strategy
  • investment logic
  • CMC & product readiness
  • commercial & access viability
  • development feasibility

outcome

milestone value

choose a path that creates strategic value, uses resources effectively and opens the right opportunities for what comes next

02 / why paiva

turn milestone ambition into a coherent development strategy

paiva connects strategic objectives, evidence requirements and available resources to help teams evaluate development choices and maintain a coherent direction

01

evidence-grounded, value-led strategy

indication-specific development, precedent and landscape intelligence combine to define what the milestone must establish to support differentiated value

the milestone's value, not just its completion

02

cross-functional decision modeling

interactively model how development choices affect evidence, dependencies, resources and future options

understand what each choice establishes and commits you to

03

living strategic intelligence

keep rationale, decisions and priorities connected as team assumptions, development outcomes and relevant external evidence change

know why your strategy holds and when to reconsider it

connect what matters, how you could get there and what changes along the way

03 / how it works

from strategic ambition to informed commitment

three connected stages turn program evidence and objectives into development choices, a full strategic assessment and a team-approved living strategy

  1. define

    what must the milestone establish to create differentiated value?

    combine program evidence, indication intelligence, objectives and constraints to propose connected development, differentiation and investment theses

    outputstrategic alignment briefteam-confirmed theses · evidence requirements · critical assumptions · strategic gaps

    what makes the program worth advancing, meaningfully different and compelling to future investors?

  2. evaluate

    which path best advances the milestone objectives?

    interactively select, defer and sequence activities, then model their implications for evidence, dependencies, time, resources and future options

    outputdevelopment path comparisonswhat each path generates, defers and commits the team to · shared exposures · cross-functional trade-offs
  3. commit

    what can the team confidently stand behind?

    select a candidate, conduct the full cross-functional strategic assessment, review the rationale and authorize a strategy with clear accountabilities

    outputliving development strategyapproved path · decision rationale · accepted exposures and owners · priority actions · decision gates · reassessment conditions
    return to evaluate

the living strategy

a strategy that outlives the meeting

the approved assessment stays linked to the relevant evidence, team assumptions, accountable decisions and next actions

  1. team assumptions revised · relevant landscape evidence monitored · activity outcomes recorded
  2. affected theses, exposures, dependencies and priorities reassessed
  3. next priority actions and changes proposed · team reviews and approves

source facts are never overwritten, team-entered assumptions are versioned with history, and paiva proposes revised priorities — substantive scientific interpretations are reassessed and reviewed, and only the team approves new commitments

  • assumptions updated

    a change in financing or execution constraints prompts review of the committed path

  • landscape intelligence

    new relevant competitor or regulatory evidence prompts review of affected theses and evidence needs

  • outcomes recorded

    completed development work is logged, updates the evidence picture and informs proposed next priority actions

04 / the intelligence

grounded in development evidence, informed by precedent and landscape intelligence

paiva draws on indication-specific, source-linked clinical and development evidence, regulatory guidance, relevant precedents and multi-stakeholder and market landscapes to inform program-specific strategic decisions

paiva goes beyond surfacing intelligence — it connects relevant evidence to development choices, commitments and the decisions that follow

01 intelligence

selected intelligence inputs

published evidence · regulatory guidance · development precedents · clinical and competitive landscapes · stakeholder perspectives

02 program-specific judgment

program-specific interpretation

what applies, what remains uncertain, what the evidence implies and which assumptions need testing

03 strategic direction

full cross-functional strategic assessment

connected theses · requirements and dependencies · therapeutic value and investment logic · functional implications · accepted exposures · priority actions and decision gates

paiva assesses where each precedent applies, where the analogy breaks down, and what those distinctions mean for the development strategy

05 / built from experience

built from real drug development experience

Sophia Lobo

founder, paiva

paiva was founded following four years in commercial strategy at Beckley Psytech, bringing experience across clinical evidence, therapeutic differentiation, patient perspectives and cross-functional development decisions into a specialist intelligence platform

advised by leaders across drug development, commercialization and software venture

Robert Conley, MD

neuroscience · clinical development · pharma leadership

former Chief Research & Development Officer, atai Beckley; former Chief Science Officer, Neuroscience, Eli Lilly & Co

Rebecca Verity

commercial strategy · pharma leadership

Chief Executive Officer, CaReMe Global; former Chief Commercial Officer, Beckley Psytech; former UK/Ireland commercial director, Johnson & Johnson

Frank Moscow

venture investment · company building

Oregon Venture Fund, Board of Advisors and Investment Committee

06 / contact

make your next development decision one you can defend

see how paiva brings evidence, development-path modeling and living strategic intelligence together for your program

one asset. one milestone. a decision you can defend

interested in a founding beta partnership?

founding beta partnership inquiry

confidential program information is discussed after scope, security and data-handling arrangements are agreed

or write to sophia@paivahq.com